Literature DB >> 2166552

Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA.

A Hertel1, R P Baum, M Lorenz, T Baew-Christow, A Encke, G Hör.   

Abstract

Using the intact monoclonal IgG1 anti-CEA antibody BW 431/26 (Behringwerke Marburg, FRG) labelled with 99mTc by a new labelling procedure (Schwarz method), 72 patients suspected of tumour recurrences (colorectal cancer, n = 59) and with rising serum carcinoembryonic antigen (CEA) levels were studied. Sixty-nine of 72 studies had a positive result by immunoscintigraphy of which 52 have since been proven histologically/clinically. In six patients only immunoscintigraphy revealed a tumour recurrence while all other diagnostic modalities were negative. Of 52 studies 46 were true positive (diagnostic sensitivity 88%). In this series there was one false positive result. About one-third of all patients injected with the antibody developed a human anti-mouse response (HAMA), but no severe side effects were seen even after four applications. For the follow-up of colorectal and other CEA positive adenocarcinomas this 99mTc-labelled monoclonal antibody seems to be very promising in patients with rising serum CEA, especially if conventional diagnostic imaging procedures remain negative.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2166552      PMCID: PMC2149521     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  3 in total

1.  Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas.

Authors:  K Bosslet; A Steinsträsser; A Schwarz; H P Harthus; G Lüben; L Kuhlmann; H H Sedlacek
Journal:  Eur J Nucl Med       Date:  1988

2.  99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results.

Authors:  R P Baum; A Hertel; M Lorenz; A Schwarz; A Encke; G Hör
Journal:  Nucl Med Commun       Date:  1989-05       Impact factor: 1.690

3.  Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.

Authors:  R W Schroff; K A Foon; S M Beatty; R K Oldham; A C Morgan
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

  3 in total
  6 in total

Review 1.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  Value of radioimmunoscintigraphy with technetium-99m labelled anti-CEA monoclonal antibody (BW431/26) in the detection of colorectal cancer.

Authors:  M Poshyachinda; T Chaiwatanarat; N Saesow; S Thitathan; N Voravud
Journal:  Eur J Nucl Med       Date:  1996-06

3.  Radioimmunolocalization of human pancreatic carcinoma xenograft by 99mTc-labeled YPC3 monoclonal antibody.

Authors:  Q Chen; S Yuan
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 4.  Follow-up plans after treatment of primary colon and rectum cancer.

Authors:  G Steele
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

5.  Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.

Authors:  M R Buist; P Kenemans; G J van Kamp; H J Haisma
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

6.  89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding.

Authors:  Emilie M J van Brummelen; Marc C Huisman; Linda J de Wit-van der Veen; Tapan K Nayak; Marcel P M Stokkel; Emma R Mulder; Otto S Hoekstra; Danielle J Vugts; Guus A M S Van Dongen; Henk M Verheul; Stefan Evers; Jean J L Tessier; Jose Saro; Jan H M Schellens; C Willemien Menke-van der Houven van Oordt
Journal:  Oncotarget       Date:  2018-05-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.